Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease

Karsten M. Strauss, L. Miguel Martins(University of Cambridge), Hélène Plun‐Favreau(Cancer Research UK), Frank P. Marx(University of Tübingen), Sabine Kautzmann(University of Tübingen), Daniela Berg(University of Tübingen), Thomas Gasser(University of Tübingen), Zbginiew Wszolek, Thomas Müller(Ruhr University Bochum), Antje Bornemann(University of Tübingen), Hartwig Wolburg(University of Tübingen), Julian Downward(Cancer Research UK), Olaf Rieß(University of Tübingen), Jörg B. Schulz(University of Göttingen), Rejko Krüger(University of Tübingen)
Human Molecular Genetics
June 16, 2005
Cited by 566Open Access
Full Text

Abstract

Recently targeted disruption of Omi/HtrA2 has been found to cause neurodegeneration and a parkinsonian phenotype in mice. Using a candidate gene approach, we performed a mutation screening of the Omi/HtrA2 gene in German Parkinson's disease (PD) patients. In four patients, we identified a novel heterozygous G399S mutation, which was absent in healthy controls. Moreover, we identified a novel A141S polymorphism that was associated with PD (P<0.05). Both mutations resulted in defective activation of the protease activity of Omi/HtrA2. Immunohistochemistry and functional analysis in stably transfected cells revealed that S399 mutant Omi/HtrA2 and to a lesser extent, the risk allele of the A141S polymorphism induced mitochondrial dysfunction associated with altered mitochondrial morphology. Cells overexpressing S399 mutant Omi/HtrA2 were more susceptible to stress-induced cell death than wild-type. On the basis of functional genomics, our results provide a novel link between mitochondrial dysfunction and neurodegeneration in PD.


Related Papers